Scandinavian ChemoTech receives a new patent on the Japanese market
Scandinavian ChemoTech has been notified that the patent authority in Japan has approved the Company's patent relating to the unique IQwave™, vetIQure™, probe and the unique electrodes that the TSE™ treatment kit consists of.
The approved patent protects both the unique probe, which the doctor and veterinarian hold, as well as the unique electrodes (needles) that are used to deliver the dynamic and tumour specific pulse in the treatment of patients.
The probe has unique properties that allow you to adjust how large an area you want to treat. Because the electrodes can be attached in various configurations in the same probe, Scandinavian ChemoTech can create significant cost benefits for healthcare providers. This is because the clinics do not have to buy several different accessories to be able to carry out the TSE treatments, within both the company's Human Care and Animal Care operations.
The innovators behind this patent are Mohan Frick, Bertil Persson and Johan Marnfeldt.
“The fact that the Company continues to develop and achieve new successes in the patent portfolio feels really good for our future market establishments. As Japan is one of the world's largest countries for medical technology, this patent could be of great importance to ChemoTech in the future. ”- says Mohan Frick, CEO of Scandinavian ChemoTech
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
